Bruno Silva-Santos

Bruno Silva-Santos is a Full Professor and Director of Immuno-Oncology at the Faculty of Medicine of the University of Lisbon, and a senior Group Leader at the Gulbenkian Institute for Molecular Medicine. He was a Group Leader and Vice-Director of the Institute of Molecular Medicine (iMM) in Lisbon, Portugal until 2024. He did his PhD in Immunology at Cancer Research UK (The London Research Institute), and trained as a post-doc at King’s College London, before establishing his own group at iMM in 2006. His research, which has been funded, among others, by the European Research Council and the la Caixa Foundation, is mostly dedicated to gamma-delta T cells, having dissected novel molecular mechanisms of their differentiation and tumor cell recognition, published in over 100 papers in top international peer-reviewed journals. In 2019, Bruno Silva-Santos was elected Member of European Molecular Organization in recognition of his scientific contributions. His translational work on Immuno-Oncology was further recognized with awards from Pfizer, AstraZeneca, Janssen and Bial; and the nomination as Honorary Member of the European Academy of Tumor Immunology. His work also constituted the basis for a start-up company focused on cancer immunotherapy, Lymphact, whose proprietary technology has been acquired by Takeda Pharmaceutical and is currently under clinical testing in 3 centers the USA (NCT05886491).